Myeloma Paper of the Day, July 23rd, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: KRd induction, ASCT, KRd consolidation, & Rd maintenance for high-risk smoldering myeloma -> 31% of patients have undetectable MRD at 4 years & 92% OS at 70 month.
Strong data but no cure & 7 deaths.”
Source: Robert Orlowski/X
Authors: María-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, Verónica González-Calle, Marta Sonia Gonzalez, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel Angel Alvarez Rivas, Joan Bargay, Ana Pilar Gonzalez-Rodriguez, Adrián Alegre, Fernando Escalante, María Belén Iñigo Rodríguez, Javier De La Rubia, Ana Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T Hernández 25, Javier Lopez Jiménez, Marta Reinoso-Segura, Aránzazu García Mateo, Enrique M Ocio, Bruno Paiva, Noemi Puig, M Teresa Cedena, Joan Bladé, Juan Jose Lahuerta, and Jesus F San-Miguel.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
